|
30.01.2025 15:00:00
|
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
ORION CORPORATION
PRESS RELEASE
30 JANUARY 2025 at 16.00 EET
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
Orion Corporation ("Orion”) and Invenra Inc. ("Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body® platform.
Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads. Orion will be responsible for the selection of targets and will be solely responsible for the development, manufacturing, and global commercialisation of these candidates. The agreement provides Orion with commercial licenses for up to two bispecific antibodies.
"Partnering with Invenra represents an important step in Orion’s strategy to expand our portfolio in the bispecific antibody space,” said Antti Haapalinna, Vice President, Head of External Science & Partnering R&D, Orion. "Invenra’s cutting-edge bispecific discovery platform, combined with Orion’s expertise in development and commercialisation, will accelerate the creation of impactful new therapies for patients worldwide.”
"This collaboration highlights the strength and versatility of our B-Body® platform in addressing complex biological challenges,” said Roland Green, CEO of Invenra. "We are thrilled to work with Orion, a company that shares our commitment to delivering innovative therapies that address critical unmet medical needs.”
This discovery collaboration combines Invenra’s advanced engineering expertise in bispecific antibody discovery with Orion’s established track record in pharmaceutical innovation, setting the stage for the development of next-generation therapeutic solutions.
About Invenra, Inc.
Invenra, Inc. is a biotechnology company leveraging proprietary platform technologies to pioneer the discovery and development of multispecific biologics, including bispecific antibodies, through its innovative B-Body® platform. Invenra partners with leading pharmaceutical and biotechnology companies to create transformative therapies for cancer, autoimmune diseases, infectious diseases, and other conditions. For more information, visit www.invenra.com.
About Orion Corporation
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Contact person:
Antti Haapalinna, Vice President, Head of External Science & Partnering R&D, Orion Corporation
tel. +358 10 426 7670
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
Nachrichten zu Orion Corporation (New) (B)
|
24.02.25 |
Ausblick: Orion B legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
|
10.02.25 |
Erste Schätzungen: Orion B mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
|
15.01.25 |
Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024 (GlobeNewswire) | |
|
24.10.24 |
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule (GlobeNewswire) | |
|
14.10.24 |
Erste Schätzungen: Orion B informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu Orion Corporation (New) (B)
📈 Zitat: „Digitalisierung beginnt nicht bei der Technik – sie beginnt beim Menschen.“ 🔎
Wie gelingt eine erfolgreiche Verbindung zwischen Tradition und Innovation im Bankwesen? Und welche Rolle spielt eine starke Führungspersönlichkeit dabei? In dieser Ausgabe des BX Morningcall tauchen wir tief ein in die Zukunft des Schweizer Bankgeschäfts – gemeinsam mit Melek Ates, der neuen Leiterin für das Privat- und Firmenkundengeschäft bei der Bank WIR. Sie bringt nicht nur über 30 Jahre Bankerfahrung mit, sondern auch frische Impulse in einer Zeit des Umbruchs und der digitalen Transformation.
Im Gespräch mit François Bloch und David Kunz gibt Melek Ates spannende Einblicke in ihre Vision für die Bank WIR, ihre Perspektiven auf den Schweizer KMU-Markt und ihre ganz persönliche Führungsphilosophie. Es geht um mehr als nur Zahlen – es geht um Werte, Wandel und Weitblick. Was macht Genossenschaftsbanken wie die Bank WIR besonders? Wie gelingt die digitale Transformation in einem traditionell geprägten Sektor? Und warum stehen dabei immer die Menschen im Mittelpunkt?
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Orion Corporation (New) (B) | 45.00 | 12.09% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zum Wochenauftakt: SMI höher erwartet -- DAX vor unbewegtem Start -- Asiens Börsen im PlusDer heimische Aktienmarkt dürfte freundlich in die Woche starten. Der deutsche Aktienmarkt wird unterdessen stabil erwartet. An den wichtigsten asiatischen Märkten geht es am Montag nach oben.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |